Stamford, CT (Press Release) – Imbrium Therapeutics L.P., a clin­i­cal-stage bio­pharma­ceu­tical com­pany and operating sub­sid­i­ary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, today announced that they have enrolled the first patient in the expansion stage of a Phase 1/2 clin­i­cal trial of tino­sta­mus­tine, an inves­ti­ga­tional treat­ment, in patients with re­lapsed refractory (R/R) hema­to­logic malig­nan­cies in the U.S. and Europe.

Following a dose escalation trial to estab­lish­ tolerability, this expansion phase seeks to in­ves­ti­gate the over­all response rate, duration of response and safety of five cohorts of patients with R/R cancers, …

Stamford, CT (Press Release) – Purdue Pharma L.P. today announced successful completion of a first-in-human Phase 1 dose escalation study of tino­sta­mus­tine in patients with re­lapsed or refractory hema­to­logical malig­nan­cies for which there are no avail­able ther­a­pies. The study eval­u­ated the safety and phar­ma­co­ki­netics, and sought to determine the maximum tolerated dose and inform a Phase 2 dose of tino­sta­mus­tine.¹

The multi-acting ther­apy can­di­date tino­sta­mus­tine, pre­vi­ously known as EDO-S101, is a novel and poten­tially first-in-class alkylating deacetylase inhibitor (AK-DACi) ther­apy being studied for its poten­tial to im­prove access to the DNA strands …

Basel, Switzerland (Press Release) – Mundipharma EDO GmbH (Early Development in Oncology) has announced the initiation of a first-in-human clin­i­cal trial of its inves­ti­ga­tional drug can­di­date EDO-S101. A first in class, fusion molecule - S101 is cur­rently being developed for the treat­ment of re­lapsed-refractory (RR) haematological malig­nan­ces. This phase 1 study is designed to eval­u­ate the safety and tolerability of ascending doses of EDO-S101 and will be conducted at several sites across the United States and Europe.

EDO-S101 is the first rep­re­sentative of the A-DAC principle, a new ap­proach in chemo­ther­apy that uses …